Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Hepatology. 2018 May 2;68(2):691–706. doi: 10.1002/hep.29833

Figure 6. miR-155 expression in human samples.

Figure 6

(A) Hepatic expression of miR-155 evaluated by qPCR in liver samples of compensated cirrhosis (n=8), decompensated cirrhosis (n=11) and AIH patients (n=15) and control livers (n=8) * p<0.05; ** p<0.01 vs. control livers; $ p<0.05 vs. decompensated and compensated cirrhosis (B) Expression of miR-155 in peripheral blood mononuclear cells (PBMC) of AIH patients (n=15), decompensated cirrhotic patients (n=10), compensated cirrhotic patients (n=6) and control individuals (n=6) ** p<0.01, ***p<0.001 vs. control individuals. (C) Expression of miR-155 in PBMC of debutant AIH patients before treatment (Pre-treatment AIH, n=8) and AIH patients undergoing immunosuppressive treatment (Treated AIH, n=7) and control individuals (n=6).